Rubric Capital Management (New York)’s ARS Pharmaceuticals SPRY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64.2M	Buy	8,000,000 +1,800,000	+29%	+$17.3M	0.79%	31
2025 Q4	$72.2M	Buy	6,200,000 +1,700,000	+38%	+$16.5M	0.86%	30
2025 Q3	$45.2M	Buy	4,500,000 +3,205,122	+248%	+$46M	0.61%	42
2025 Q2	$22.6M	Buy	1,294,878 +265,777	+26%	+$3.83M	0.36%	49
2025 Q1	$12.9M	Buy	+1,029,101	New	+$12.4M	0.23%	49
2024 Q3	–	Sell	-639,203	Closed	-$5.44M	–	74
2024 Q2	$5.44M	Hold	639,203	–	–	0.14%	60
2024 Q1	$6.53M	Hold	639,203	–	–	0.19%	60
2023 Q4	$3.5M	Hold	639,203	–	–	0.13%	54
2023 Q3	$2.42M	Sell	639,203 -2,160,000	-77%	-$14.2M	0.1%	60
2023 Q2	$18.8M	Sell	2,799,203 -681,509	-20%	-$4.55M	0.8%	37
2023 Q1	$22.7M	Buy	3,480,712 +490,148	+16%	+$3.77M	0.9%	40
2022 Q4	$25.5M	Buy	2,990,564 +295,394	+11%	+$1.92M	1.12%	30
2022 Q3	$14.2M	Buy	2,695,170 +1,708,717	+173%	+$8.42M	0.72%	38
2022 Q2	$4.18M	Buy	+986,453	New	+$3.44M	0.22%	67